Ride Therapeutics raises $8M seed for non-viral gene delivery
What's the deal? Ride TherapeuticsDealroom has a profile for this one. Try Dealroom →, a UK-based in vivo gene medicine delivery platform, has raised $8 million in a seed round announced in September 2026. The company designs and screens non-viral vectors to carry genetic payloads inside living systems.
What's the endgame? Ride runs an ultra-high-throughput nanoengineering system that builds diverse libraries of non-viral carriers and tests them directly in living organisms. It has screened more than 1,000,000 unique non-viral vectors and generated billions of delivery data points.
Why non-viral? Viral vectors dominate gene therapy but come with manufacturing and immune-response limits. Non-viral delivery aims to sidestep those constraints — and Ride is betting that scale of experimentation, not incremental design, unlocks better carriers.
The signal: At $8 million, the round sits in the top 5% of seed deals ever recorded for UK health startups, based on 2,038 comparable rounds. That size signals investor conviction in a platform approach to one of gene medicine's hardest problems: getting the payload to the right place.
Image credit: Generated with Gemini
